Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL

Timeline

Start Date

November 30, 1998

Study Completion Date

May 31, 2003

Conditions

Melanoma (Skin)

Interventions

BIOLOGICAL

aldesleukin

BIOLOGICAL

gp209-2M antigen

BIOLOGICAL

incomplete Freund's adjuvant

Trial Locations (1)

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00019487 - Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter